131 related articles for article (PubMed ID: 26181600)
1. Effect of infliximab on inflammatory bowel disease with Takayasu arteritis: case series and review of the literature.
Minami N; Nakase H; Yoshino T; Yamada S; Toyonaga T; Honzawa Y; Matsuura M; Chiba T
Clin J Gastroenterol; 2013 Jun; 6(3):226-30. PubMed ID: 26181600
[TBL] [Abstract][Full Text] [Related]
2. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
[TBL] [Abstract][Full Text] [Related]
3. Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature.
Comarmond C; Plaisier E; Dahan K; Mirault T; Emmerich J; Amoura Z; Cacoub P; Saadoun D
Autoimmun Rev; 2012 Jul; 11(9):678-84. PubMed ID: 22155781
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
[TBL] [Abstract][Full Text] [Related]
5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
6. Clinical observations on infliximab treatment of infantile onset Takayasu arteritis.
Kang M; Lai J; Zhang D; Xu Y; Zhu J; Li M
Pediatr Rheumatol Online J; 2022 Aug; 20(1):61. PubMed ID: 35927694
[TBL] [Abstract][Full Text] [Related]
7. Refractory Takayasu arteritis successfully treated with infliximab.
Maffei S; Di Renzo M; Santoro S; Puccetti L; Pasqui AL
Eur Rev Med Pharmacol Sci; 2009; 13(1):63-5. PubMed ID: 19364087
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic features and genetic background of inflammatory bowel disease complicated with Takayasu arteritis.
Akiyama S; Fujii T; Matsuoka K; Yusuke E; Negi M; Takenaka K; Nagahori M; Ohtsuka K; Isobe M; Watanabe M
J Gastroenterol Hepatol; 2017 May; 32(5):1011-1017. PubMed ID: 28449344
[TBL] [Abstract][Full Text] [Related]
9. Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report.
Masui S; Yonezawa A; Izawa K; Hayakari M; Asakura K; Taniguchi R; Isa M; Shibata H; Yasumi T; Nishikomori R; Takita J; Matsubara K
J Pharm Health Care Sci; 2019; 5():9. PubMed ID: 31073411
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
11. A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients.
Veerappan SG; Healy M; Walsh B; O'Morain CA; Daly JS; Ryan BM
Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1335-44. PubMed ID: 27508327
[TBL] [Abstract][Full Text] [Related]
12. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
[TBL] [Abstract][Full Text] [Related]
13. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
15. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
16. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment.
Rolandsdotter H; Marits P; Sundin U; Wikström AC; Fagerberg UL; Finkel Y; Eberhardson M
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272355
[TBL] [Abstract][Full Text] [Related]
17. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
[TBL] [Abstract][Full Text] [Related]
18. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
[TBL] [Abstract][Full Text] [Related]
19. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
20. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
Billiet T; Papamichael K; de Bruyn M; Verstockt B; Cleynen I; Princen F; Singh S; Ferrante M; Van Assche G; Vermeire S
J Crohns Colitis; 2015 Dec; 9(12):1120-6. PubMed ID: 26351386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
